Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
US9688695B2 · kind B2 · utility
9Cited by
1References
51Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2013 |
| Grant date | Jun 27, 2017 |
| Priority date | — |
| Expiry date | Jun 19, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.